EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review

Bente Braun iD, Felix Fischbach, Lena Kristina Pfeffer, Johanna Richter, Dietlinde Janson, Nicolaus M Kröger, Alice Mariottini, Christoph Heesen iD, Vivien Häußler iD

European Journal of Neurology · 2024-12 · 31 (12)

DOI: 10.1111/ene.16427 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Neurology, online erschienen am 05.08.2024. Verfasst von Bente Braun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroimmunology and Multiple Sclerosis, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Sclerosis, Chronic Progressive, Transplantation, Autologous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The aim was to determine the value of autologous haematopoietic stem cell transplantation (aHSCT) as a therapeutic intervention for progressive multiple sclerosis (PMS) based on a systematic review of the current literature.

Methods

All studies from the databases PubMed and Google Scholar published in English before February 2024 which provided individual data for PMS patients were systematically reviewed. PICO was defined as population (P), primary progressive MS and secondary progressive MS patients; intervention (I), treatment with aHSCT; comparison (C), none, disease‐modifying therapy treated/relapsing–remitting MS cohorts if available; outcome (O), transplant‐related mortality, progression‐free survival (PFS) and no evidence of disease activity.

Results

A total of 15 studies met the criteria including 665 patients with PMS (74 primary progressive MS, 591 secondary progressive MS) and 801 patients with relapsing–remitting MS as controls. PFS data were available for 647 patients. PMS patients showed more severe disability at baseline than relapsing–remitting MS patients. The average transplant‐related mortality for PMS in 10 studies was 1.9%, with 10 deaths in 528 patients. PFS ranged from 0% to 78% in PMS groups 5 years after treatment initiation, demonstrating a high variability. No evidence of disease activity scores at 5 years ranged from 0% to 75%.

Conclusion

Based on the available data, aHSCT does not halt progression in people with PMS. However, there appears to be evidence of improved outcome in selected patients. Due to the heterogeneity of the available data, more comprehensive clinical trials assessing the efficacy of aHSCT across different patient groups are urgently needed to reduce variability and improve patient stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMultiple Sclerosis, Chronic ProgressiveTransplantation, AutologousHumans

Stichwörter der Autor:innen

autologous hematopoietic stem cell transplantationno evidence of disease activityprogression‐free survivalprogressive multiple sclerosistransplant‐related mortality

Autor:innen und Institutionen

  • Institute of Neuroimmunology and Multiple Sclerosis, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Department Neurology II, Careggi University Hospital, Florence, Italy.
  • Department of Neurology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Bente Braun, Christoph Heesen, Vivien Häußler

Zitieren

APA

Braun, B., Fischbach, F., Pfeffer, L. K., Richter, J., Janson, D., Kröger, N. M., Mariottini, A., Heesen, C., & Häußler, V. (2024). Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16427

Vancouver

Braun B, Fischbach F, Pfeffer LK, Richter J, Janson D, Kröger NM, et al. Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16427

BibTeX
@article{Braun2024,
  author = {Braun, Bente and Fischbach, Felix and Pfeffer, Lena Kristina and Richter, Johanna and Janson, Dietlinde and Kröger, Nicolaus M and Mariottini, Alice and Heesen, Christoph and Häußler, Vivien},
  title = {Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {12},
  doi = {10.1111/ene.16427}
}
Kostenlos starten →